Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer
- 29 October 2014
- journal article
- Published by Springer Nature in Surgery Today
- Vol. 45 (1) , 68-77
Abstract
This study was designed to clarify whether preoperative tumor size is an independent prognostic factor (IPF) for patients with Borrmann type III gastric cancer. The study group comprised 350 patients with Borrmann type III gastric cancer. We performed a log-rank plot analysis to establish the threshold value of preoperative tumor size for the prediction of overall survival (OS). Factors with P Peritoneal lavage cytology (CY) was the strongest IPF for patients with Borrmann type III gastric cancer (P P = 0.007) and preoperative tumor size (P = 0.018) were significant IPFs in the CY0 patients. Patients with a preoperative tumor size of 80 %. Preoperative tumor size is an IPF for patients with Borrmann type III gastric cancer and CY0. Thus, preoperative tumor size may be a useful factor for deciding on whether neoadjuvant chemotherapy is indicated.Keywords
This publication has 25 references indexed in Scilit:
- Stage-Stratified Analysis of Prognostic Significance of Tumor Size in Patients with Gastric CancerPLOS ONE, 2013
- Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgerySurgery Today, 2012
- Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 studyGastric Cancer, 2012
- Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1Gastric Cancer, 2011
- Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 PatientsAnnals of Surgical Oncology, 2010
- A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study)European Journal of Surgical Oncology, 2009
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Gastric cancer treated in 1991 in Japan: data analysis of nationwide registryGastric Cancer, 2006
- Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population DatabaseJournal of Clinical Oncology, 2005
- Relevant Prognostic Factors in Gastric CancerAnnals of Surgery, 1998